The Group holds WDA, MIA, and MS licenses and specializes in sourcing and licensing generic pharmaceutical products for the UK market. The company has multiple marketing authorizations, in the UK, alongside multiple new applications currently under regulatory review in the UK. Farmak Pharmaceuticals UK Ltd will retain the group’s founder and team post-acquisition, aiming to bolster its business development capabilities in the UK through an established network of international partners.

This transaction follows careful preparation and evaluation of various strategic options. The A&S Group met all legal regulations and aligns with Farmak International’s high ethical and corporate standards.

The acquisition marks another significant step in Farmak International’s global expansion strategy. It follows recent strategic moves, including the acquisition of Polish Symphar in March 2024, 2023 year’s acquisitions in the Czech Republic and Slovak Republic, and a brownfield investment in Spain in 2022.

Viktor Kostiuk, CEO of Farmak International:

We are thrilled to welcome the A&S Group into the Farmak International family. This acquisition aligns perfectly with our strategy of expanding our footprint in key markets. By integrating the groups established UK presence and expertise in generic pharmaceuticals, we are poised to accelerate our growth and continue delivering high-quality medicines to patients across the region. This acquisition is a testament to our commitment to global leadership in pharmaceuticals, and I am confident that, together, we will build a stronger future.

Marc Westermann, Chief Commercial Officer (CCO) of Farmak International:

The acquisition of the A&S Group marks an exciting new chapter for Farmak International in the UK. The Groups market knowledge and established partnerships will enhance our commercial capabilities throughout our UK and international markets, allowing us to offer a broader range of generic pharmaceutical products to healthcare providers and patients. With its portfolio and expertise, we are well-positioned to meet the growing demand for affordable medicines and continue to strengthen our presence in the UK and beyond.

Marc Hourigan, CEO of Farmak Pharmaceuticals UK Ltd:

From a business development perspective, the acquisition of The A&S Group opens up significant opportunities for Farmak UK and our International affiliates. By leveraging the groups extensive network and commercial expertise, we will be able to fast-track our expansion into new therapeutic areas and markets within the UK and our affiliates in International markets. Their strong relationships with healthcare providers and industry stakeholders will be invaluable as we grow our product offerings and reinforce our commitment to innovation and quality in every market we serve.

About Farmak International

Farmak International, founded in 1925, is a thriving pharmaceutical company focused on the research, development, manufacturing, and global distribution of generic medicines. With state-of-the-art manufacturing and R&D facilities in Ukraine and Spain, Farmak International has built a strong global presence. The company operates 12 commercial offices worldwide, including in Switzerland, the UK, Spain, Poland, the Slovak Republic, the Czech Republic, the UAE, Ukraine, Vietnam, Uzbekistan, Kazakhstan, and Kyrgyzstan.

Farmak International exports its products to 60 countries, including 15 EU Member States, as well as markets in Central and South America, the Middle East, Asia, Africa, and Australia. This extensive network underscores the company’s commitment to delivering high-quality medicines worldwide.

About Farmak Pharmaceuticals UK Ltd

Farmak Pharmaceuticals UK Ltd serves as a key regional hub for expanding market presence, facilitating partnerships, and delivering high-quality pharmaceutical products across the UK and the Republic of Ireland.

Adviser

FinPoint investment banking firm acted as the exclusive financial adviser to Farmak International on this acquisition.